CONFERENCE ON BREAST AND PROSTATE CANCER

乳腺癌和前列腺癌是最常见的 男性和女性的激素依赖性恶性肿瘤。 实质性进展 在研究中发现， 突变、缺失、扩增或重排的元件 有助于疾病的发病机制。 其中包括新 关于显性作用癌基因如erbB1、erbB2和erbB3的表达的数据， erbB3，以及抑制性遗传元件如NM 23，P53和 RB. 这些遗传因素与 增殖控制，以诱导异常生长和恶性行为， 也在快速推进。 这次会议将旨在达成共识 这些遗传因素参与乳腺癌的机制， 前列腺疾病以及这些信息对 诊断、预后和治疗。 一个核心的，新颖的特点， 会议将聚集对乳腺癌和乳腺癌感兴趣的科学家， 前列腺癌，以促进思想交流。 两个乳房 前列腺癌的发生和发展依赖于类固醇激素。 两种癌症的进展也取决于生长的相互作用。 癌基因和抑癌基因的进行性遗传变化。 这次会议提供了一个独特的机会，邀请领导人在 每个领域的细胞和分子研究，以比较数据，修改他们的 工作假说的调节恶性肿瘤，并讨论新的 治疗方法。 这两种疾病一起折磨大约 10%的男性和女性在生物学上有显著的相似之处 和治疗策略中的作用。

Breast cancer and prostate cancer are overwhelmingly the most common hormone dependent malignancies of men and women. Substantial progress has been made in research leading to identification of specific genetic elements whose mutation, deletion, amplification or rearrangement contribute to the pathogenesis of the diseases. This includes both new data on expression of dominantly acting oncogenes such as erbBl, erbB2, and erbB3, and the loss of repressive genetic elements such as NM23, P53, and Rb. The mechanisms by which these genetic elements interact with proliferative controls to induce abnormal growth and malignant behavior is also rapidly advancing. This meeting will be aimed at developing consensus on the mechanisms of involvement of these genetic elements in breast and prostate disease and the impact of this information on approaches to diagnosis, prognosis, and therapy. A central, novel feature of this meeting will be to assemble scientists interested in both breast and prostate cancer to facilitate cross-fertilization of ideas. Both breast and prostate cancer depend upon steroid hormones for onset and progression. Progression of both cancer types also depends on interaction of growth factors and progressive genetic changes in oncogenes and anti-oncogenes. This conference provides a unique opportunity to invite the leaders in cellular and molecular studies of each field to compare data, modify their working hypotheses of regulation of malignancies, and discuss new therapeutic approaches. These two diseases together afflict approximately 10% of both men and women and have remarkable similarities in the biology of their onset and in therapeutic strategies.